放射治疗联合细胞周期蛋白依赖性激酶4/6抑制剂:一项多机构安全性与毒性研究
该回顾性队列研究纳入加拿大阿尔伯塔省4个癌症中心2016至2020年间接受放疗的激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌患者,比较放疗联合CDK4/6抑制剂与单纯放疗的毒性。结果显示两组急性≥2级非血液学毒性发生率分别为11.5%和7%(P=0.439),倾向性评分匹配后多因素分析未显示显著关联(OR 3.13,95%CI 0.74-13.2,P=0.121)。作者建议CDK4/6抑制剂与放疗同期给药时需谨慎。
要点
- 放疗联合CDK4/6抑制剂组与单纯放疗组急性≥2级非血液学毒性发生率分别为11.5%和7%,无显著差异(P=0.439)。
- 倾向性评分匹配后多因素分析显示放疗联合CDK4/6抑制剂与急性毒性关联不显著(OR 3.13,95%CI 0.74-13.2,P=0.121)。
- 联合组急性毒性主要见于同期放疗(67%),且多数≥3级毒性记录于同期放疗。
核心结论
- 在转移性乳腺癌接受姑息放疗的女性中,未观察到CDK4/6抑制剂使用与急性≥2级非血液学毒性之间存在显著关联。
- 鉴于观察到≥3级毒性,作者建议CDK4/6抑制剂与放疗同期给药时需谨慎。
研究设计与样本
- 回顾性队列研究,纳入加拿大阿尔伯塔省4个癌症中心2016至2020年间接受放疗的激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌患者。
- 放疗联合CDK4/6抑制剂组132例患者(220个放疗部位),单纯放疗组53例患者(93个放疗部位)。
- 主要结局为放疗后30天内急性≥2级非血液学毒性,采用倾向性评分匹配创建可比队列,广义线性混合模型评估与急性毒性相关的因素。
主要发现
- 放疗联合CDK4/6抑制剂组与单纯放疗组急性≥2级非血液学毒性发生率分别为11.5%和7%(P=0.439)。
- 放疗联合CDK4/6抑制剂组与单纯放疗组急性≥3级非血液学毒性发生率分别为3.7%和0%(P=0.151)。
- 联合组急性毒性主要见于同期放疗(67%),且多数≥3级毒性记录于同期放疗。
- 倾向性评分匹配后多因素分析显示,放疗联合CDK4/6抑制剂与单纯放疗相比,急性毒性关联不显著(OR 3.13,95%CI 0.74-13.2,P=0.121)。
临床怎么用
- 作者建议,CDK4/6抑制剂与放疗同期给药时需谨慎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to investigate radiation therapy (RT) toxicity when given with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) compared with RT alone. METHODS AND MATERIALS: We conducted a retrospective cohort study of patients with hormonal receptor-positive and human epidermal growth factor-2 negative metastatic breast cancer treated with RT at 4 cancer centers in Alberta, Canada, between 2016 and 2020. Toxicity in patients treated with RT within 30 days of initiating to discontinuing CDK4/6i (RT + CDK4/6i) was compared with toxicity of RT in CDK4/6i-naïve patients (RT alone). The primary outcome was acute grade (G) 2 or higher, nonhematological toxicity within 30 days of RT. We also explored toxicity based on the timing of RT (prior, concurrent, post) in relation to CDK4/6i. Propensity score matching was applied to create comparable cohorts. A generalized linear mixed model was used to evaluate factors associated with acute toxicity. RESULTS: One hundred thirty-two patients (220 RT sites) in the RT + CDK4/6i and 53 patients (93 RT sites) in RT alone were eligible. The rate of acute G2 or higher nonhematological toxicity was 11.5% versus 7%, respectively (P = .439), and acute G3 or higher nonhematological toxicity was 3.7% versus 0%, respectively (P = .151). Acute toxicity in RT + CDK4/6i group was mainly observed when RT was given concurrently (67%), with most of the G3 toxicity recorded. After propensity score matching, the association of acute toxicity with RT + CDK4/6i versus RT alone was not significant on multivariable analysis (odds ratio, 3.13; 95% confidence interval, 0.74-13.2; P = .121). CONCLUSIONS: We did not observe a significant association between CDK4/6i use and acute G2 or higher nonhematological toxicity in women with metastatic breast cancer receiving palliative RT. Given the findings of G3 toxicity, caution is advised whenever CDK4/6i is given concurrently with RT.
引用
- Al-Rashdan A, Quirk S, Roumeliotis M, et al. Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study. Int J Radiat Oncol Biol Phys. 2022. PMID: 35870712. doi:10.1016/j.ijrobp.2022.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。